This discrepancy was caused primarily by the prescriptions which guide patients with tumor PD-L1 expression ≥ 1% for pembro, while patients having tumor PD-L1 expression < 1% were guided for nivo/ipi therapy. Here, CD274 is linked to neoplasm.